Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 88,447,000, a decrease of 43% compared to RMB 155,740,000 in 2024[3] - Gross profit for 2025 was RMB 22,127,000, down 65% from RMB 62,786,000 in 2024[3] - The company reported a loss before tax of RMB 31,378,000 for 2025, compared to a profit of RMB 26,309,000 in 2024[3] - Basic and diluted loss per share for 2025 was RMB (0.03), compared to earnings of RMB 0.02 per share in 2024[4] - The company reported a net loss of RMB 29,716,000 for 2025, compared to a profit of RMB 17,204,000 in 2024[34][36] - The company recorded a net loss of approximately RMB 299 million, an increase of RMB 474 million or 270.9% (2024: RMB 175 million) due to the cumulative impact of the aforementioned factors[72] Assets and Liabilities - Total assets less current liabilities decreased to RMB 232,644,000 in 2025 from RMB 260,661,000 in 2024[6] - Non-current assets totaled RMB 57,439,000 as of December 31, 2025, slightly down from RMB 58,686,000 in 2024[5] - Cash and cash equivalents decreased to RMB 21,932,000 in 2025 from RMB 28,226,000 in 2024[5] - Trade receivables decreased to RMB 163,286,000 in 2025 from RMB 174,190,000 in 2024[5] - The total amount of bank borrowings as of December 31, 2025, was RMB 12,764,000, down from RMB 17,712,000 in 2024[43] - As of December 31, 2025, the company had net current assets of approximately RMB 1,752 million (2024: RMB 2,020 million) and cash and cash equivalents decreased by approximately RMB 63 million to about RMB 219 million (2024: RMB 282 million)[73] - The company’s trade payables increased to RMB 1,242,000 in 2025 from RMB 560,000 in 2024[41] - The company has no significant contingent liabilities as of December 31, 2025 (2024: none)[76] - As of December 31, 2025, the company's debt-to-equity ratio decreased by 1.3 percentage points to 5.5% from 6.8% as of December 31, 2024, primarily due to a reduction in interest-bearing bank borrowings[80] Revenue Sources - Revenue from medical imaging film products accounted for about 85% of total revenue in 2025, compared to 76% in 2024[17] - Revenue from medical imaging film products and software decreased by approximately RMB 603 million or 41.2% to about RMB 862 million (2024: RMB 1,465 million) due to lower average selling prices and decreased sales volume[62] - Revenue from medical imaging cloud services decreased by approximately RMB 70 million or 76.1% to about RMB 22 million (2024: RMB 92 million), following the decline in film product sales[63] Expenses - The cost of goods sold for the year was RMB 55,947,000, down from RMB 83,682,000 in 2024, reflecting a decrease of approximately 33%[29] - Other income for the year totaled RMB 6,154,000, a decrease from RMB 8,583,000 in 2024, primarily due to lower government grants[28] - The group incurred employee benefit expenses of RMB 10,711,000 in 2025, compared to RMB 11,884,000 in 2024, indicating a reduction of approximately 10%[29] - The group’s depreciation of property, plant, and equipment increased to RMB 14,038,000 in 2025 from RMB 6,562,000 in 2024, reflecting a significant rise[29] - Operating expenses increased by approximately RMB 22 million or 12.4% to about RMB 200 million (2024: RMB 178 million), mainly due to increased depreciation of property, plant, and equipment[68] Taxation - The company's income tax expense for 2025 was a credit of RMB 1,417,000, compared to an expense of RMB 8,859,000 in 2024[31] - The applicable income tax rate for the company in mainland China is 25%, with a subsidiary qualifying for a reduced rate of 15% due to high-tech enterprise status[32] Strategic Plans - The company plans to expand its customer base and strengthen its market position in Shandong Province by extending its services to other regions[53] - Strategic acquisitions and upgrades of hardware and software are intended to enhance the supply of medical imaging cloud services[53] - The company believes that developing medical imaging cloud services and expanding its product range will increase long-term revenue and strengthen its role as a one-stop medical imaging solution provider[56] - The company aims to participate in trade exhibitions to promote its brand and increase market visibility[53] Shareholder Information - The company has no plans to declare dividends for the year 2025, consistent with 2024[33] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year[89] - The annual general meeting is scheduled for May 29, 2026[92] - The company expresses gratitude to all shareholders and stakeholders for their ongoing support, as well as appreciation for the efforts and contributions of all employees[98] Corporate Governance - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[103] - The audit committee, along with the management and independent auditor, reviewed the accounting principles and policies adopted by the group, confirming that the annual performance aligns with applicable accounting standards and regulations[95] - The consolidated financial statements for the year ending December 31, 2025, have been agreed upon by the group's auditor, ensuring consistency with the audited financial statements[96] Company Background - The company was registered in the Cayman Islands on December 11, 2020, as a limited liability company[99] - The shares of the company were listed on the main board of the Hong Kong Stock Exchange on December 29, 2022[99] - The company adopted a share incentive plan on December 2, 2023, to motivate and reward employees[100] - The reporting period for the financial statements is from January 1, 2025, to December 31, 2025[100]

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 88,447,000, a decrease of 43% compared to RMB 155,740,000 in 2024[3] - Gross profit for 2025 was RMB 22,127,000, down 65% from RMB 62,786,000 in 2024[3] - The company reported a loss before tax of RMB 31,378,000 for 2025, compared to a profit of RMB 26,309,000 in 2024[3] - Basic and diluted loss per share for 2025 was RMB (0.03), compared to earnings of RMB 0.02 per share in 2024[4] - Other income for the year was RMB 6,154,000, a decrease from RMB 8,583,000 in 2024, primarily due to lower government grants[28] - The company recorded a net loss of approximately RMB 299 million, an increase of RMB 474 million or 270.9% (2024: RMB 175 million) due to the cumulative impact of the aforementioned factors[72] Assets and Liabilities - Non-current assets totaled RMB 57,439,000 as of December 31, 2025, slightly down from RMB 58,686,000 in 2024[5] - Current assets decreased to RMB 213,250,000 in 2025 from RMB 245,482,000 in 2024, reflecting a decline of 13%[5] - The company's net assets were RMB 232,276,000 as of December 31, 2025, down from RMB 260,506,000 in 2024[6] - Total bank borrowings decreased to RMB 12,764,000 in 2025 from RMB 17,712,000 in 2024, with secured borrowings remaining constant at RMB 7,500,000[43] - As of December 31, 2025, the company's debt-to-equity ratio decreased by 1.3 percentage points to 5.5% from 6.8% as of December 31, 2024, primarily due to a reduction in interest-bearing bank borrowings[80] Revenue Breakdown - Revenue from medical imaging film products accounted for approximately 85% of total revenue in 2025, compared to 76% in 2024[17] - Revenue from medical imaging film products and software decreased by approximately RMB 603 million or 41.2% to about RMB 862 million (2024: RMB 1,465 million) due to lower average selling prices and reduced sales volume[62] - Revenue from medical imaging cloud services decreased by approximately RMB 70 million or 76.1% to about RMB 22 million (2024: RMB 92 million), following the decline in film product sales[63] Operational Focus - The company is involved in the sale of medical imaging film products and the provision of medical imaging cloud services, indicating ongoing operational focus[9] - The company plans to expand its customer base and strengthen its market position in Shandong Province by extending its services to other regions[53] - Strategic acquisitions and upgrades of software and hardware are intended to enhance the supply of medical imaging cloud services[53] - The company believes that developing medical imaging cloud services and expanding its product range will enhance its long-term revenue and solidify its role as a one-stop medical imaging solution provider[56] Employee and Governance - The company has a total of 56 employees as of December 31, 2025, a slight decrease from 57 employees in the previous year[84] - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[103] Future Outlook - The medical device industry in China is expected to maintain stable growth driven by technological advancements and increasing healthcare demands[54] - The national medical insurance imaging cloud is being deployed across 27 provinces, aiming to create a unified national medical insurance imaging network by 2027[55] Shareholder Information - The company did not declare any dividends for the year 2025, consistent with 2024[33] - The board does not recommend the payment of a final dividend for 2025, consistent with the previous year[83] - The annual general meeting is scheduled for May 29, 2026[92] Compliance and Reporting - The audit committee, along with the management and independent auditor, reviewed the accounting principles and policies adopted by the group, confirming that the annual performance aligns with applicable accounting standards and regulations[95] - The consolidated financial statements for the year ending December 31, 2025, have been agreed upon by the group's auditor, ensuring consistency with the audited financial statements[96] - The annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website, containing all information required by the listing rules[97]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 Guanze Medical Information Industry (Holding) Co., Ltd. （於開曼群島註冊成立的有限責任公司） 本期間的預期虧損主要是由於下列因素的綜合影響： – 1 – （股份代號：2427） 盈利警告及內幕消息公告 財務資料更新 (1) 2025年影像膠片產品的平均售價及數量較2024年同期有所下降； (2) 銷售額由2024年的約人民幣155.7百萬元減至2025年的約人民幣88.4百萬元； 及 (3) 2025年物業、廠房及設備可能減值。 本公司現正落實本集團本期間之全年業績。本公告所載資料僅以董事會經參 考本集團現時可得的資料及本集團本期間的未經審核綜合管理賬目後作出的 初步評估為依據，尚未經核數師或本公司審核委員會審計或審閱，故可予以調 整。股東及有意投資者敬請細閱本公司本期間的全年業績公告，預期該公告將 於2026年3月底前刊發。 本公告由Guanze ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Guanze Medical Information Industry (Holding) Co., Ltd. （於開曼群島註冊成立的有限責任公司） 董事會主席 孟憲震 香港，2026年3月18日 （股份代號：2427） 於本公告日期，董事會由執行董事孟憲震先生及郭振宇先生，非執行董事Meng Cathy女士， 獨立非執行董事趙斌博士、常世旺博士及黃文顯博士組成。 董事會會議通告 Guanze Medical Information Industry (Holding) Co., Ltd.（「本公司」）董 事 會（「董 事 會」）謹此宣佈，本公司謹訂於2026年3月31日（星期二）舉行董事會會議，藉以（其 中包括）(i)審閱及酌情批准本公司及其附屬公司截至2025年12月31日止年度之 全年業績；(ii)考慮宣派末期股息（如有）；及(iii)處理任何其他事項（如有）。 承董事會命 Guanze Medi ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本聯合公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本聯合公告僅供參考，並不構成收購、購買或認購Guanze Medical Information Industry (Holding) Co., Ltd.證券的邀請或要約或成為其中一部分，亦非於任何司法權區招攬任何表決權或批准， 亦不得在與適用法律或法規相抵觸的情況下於任何司法權區出售、發行或轉讓Guanze Medical Information Industry (Holding) Co., Ltd.證券。本聯合公告不會在構成違反有關司法權區的相關 法律的情況下於或向該司法權區發佈、刊發或派發。 FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED 富德（香港）投資控股有限公司 （於香港註冊成立的有限責任公司） GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD. （於開曼群島註冊成立的 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Guanze Medical Information Industry (Holding) Co., Ltd. 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02427 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 ...

本聯合公告僅供參考，並不構成收購、購買或認購Guanze Medical Information Industry (Holding) Co., Ltd.證券的邀請或要約或成為其中一部分，亦非於任何司法權區招攬任何表決權或批准， 亦不得在與適用法律或法規相抵觸的情況下於任何司法權區出售、發行或轉讓Guanze Medical Information Industry (Holding) Co., Ltd.證券。本聯合公告不會在構成違反有關司法權區的相關 法律的情況下於或向該司法權區發佈、刊發或派發。 FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED 富德（香港）投資控股有限公司 （於香港註冊成立的有限責任公司） GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD. （於開曼群島註冊成立的有限責任公司） （股份代號：2427） 有關根據收購守則規則3.5作出的公告之 澄清公告 茲提述Guanze Medical Information Industry (Holding) Co., Ltd.（「本公司」 ...

Group 1 - A total of 136 stocks reached a 52-week high as of February 20, with GUANZE MEDICAL (02427), Asia Express (08620), and Zhipu (02513) leading the high rate at 56.29%, 39.24%, and 34.26% respectively [1] - GUANZE MEDICAL closed at 4.450, with a peak price of 4.720, marking a 56.29% increase [1] - Asia Express closed at 0.187, reaching a high of 0.220, reflecting a 39.24% increase [1] - Zhipu closed at 725.000, with a peak price of 725.000, indicating a 34.26% increase [1] Group 2 - Other notable stocks that reached new highs include Bore Power (01685) at 30.26%, Haizhi Technology Group (02706) at 25.00%, and Dachang Microline Group (00567) at 23.53% [1] - The stock performance of various companies shows significant increases, with several stocks achieving over 20% growth [1] - The data indicates a strong market trend with multiple companies experiencing substantial gains, suggesting potential investment opportunities [1]

Group 1 - As of February 12, 139 stocks reached a 52-week high, with the top three being Bohr Power (01685), GUANZE MEDICAL (02427), and Clinique Holdings (08367), achieving high rates of 80.95%, 80.84%, and 43.82% respectively [1] - Bohr Power (01685) closed at 0.690, with a peak price of 0.760, marking an increase of 80.95% [1] - GUANZE MEDICAL (02427) closed at 1.390, reaching a high of 3.020, reflecting a growth of 80.84% [1] Group 2 - Other notable stocks that reached new highs include HPC HOLDINGS (01742) with a high rate of 26.53%, and Zhipu (02513) with a high rate of 25.14% [1] - China National Heavy Duty Truck (03808) achieved a high rate of 13.26%, closing at 42.380 with a peak of 45.780 [1] - Tianjin Jianfa (02515) reached a high rate of 12.28%, closing at 0.970 with a peak of 1.280 [1] Group 3 - The report also lists stocks that experienced a decline, with Minfu International (08511) dropping by 25.00%, closing at 0.730 with a low of 0.600 [4] - Other stocks that saw significant declines include Baideli Holdings (06909) with a decrease of 20.51% and XI Ernan Samsung (07347) with a decline of 12.80% [4] - The overall market shows a mix of high-performing stocks alongside those facing downward pressure, indicating varied investor sentiment [4]

Group 1 - GuanZe Medical (02427) resumed trading with a high opening, increasing by 15.38% to HKD 1.8, with a trading volume of HKD 2.106 million [1] - The company announced that the offeror, Fude (Hong Kong) Investment, intends to acquire approximately 699 million shares from the controlling shareholder, representing about 73.6% of the total issued share capital, for a total consideration of approximately HKD 175 million [1] - Following the completion of the acquisition, the offeror and concert parties are required to make an unconditional cash offer to acquire all issued shares of the company at a cash offer price of HKD 0.25 per share, which represents a discount of approximately 84% compared to the closing price of HKD 1.56 before the suspension [1]